NHU(002001)

Search documents
新和成:黑龙江基地以生物发酵产品为核心发展领域
Zheng Quan Ri Bao· 2025-09-05 08:41
Core Viewpoint - The company is actively implementing its "Bio+" strategy through the development of a range of bio-fermentation products at its Heilongjiang base, focusing on high-value and technologically advanced offerings [2] Group 1: Company Strategy - The Heilongjiang base is positioned as a center for bio-fermentation products, with a focus on vitamins such as Vitamin C, Coenzyme Q10, Vitamin B5, B12, and amino acids like serine, cysteine, and tryptophan [2] - The company emphasizes a technology-first approach in the development of new products, aiming for a series of high-value, large-scale offerings [2] - There is a strong focus on extending the existing business's industrial chain and creating synergistic effects with current operations [2] Group 2: Research and Development - The company has established a bio-fermentation research institute to foster internal and external collaboration, aiming to stay at the forefront of biotechnology [2] - The goal is to create a comprehensive "Bio+" platform that integrates technology and products deeply [2]
新和成:新材料板块上半年营业收入为10.38亿元
Zheng Quan Ri Bao· 2025-09-05 08:41
Group 1 - The core viewpoint of the article highlights that Xinhecheng's new materials segment achieved a revenue of 1.038 billion yuan in the first half of the year, representing a 43.75% increase compared to the same period last year, driven by both volume and price increases in PPS and the HA project [2] - The new materials segment has a broad market outlook, with significant demand growth in sectors such as new energy, semiconductors, and high-end manufacturing [2] - The company plans to advance the PPS expansion project and scale up HA production in response to market demand [2]
新和成:公司专注于营养品、香精香料、高分子新材料和原料药业务
Zheng Quan Ri Bao· 2025-09-05 08:41
Core Viewpoint - The company, Xinhecheng, announced on September 5 that it is focused on the nutrition, flavor and fragrance, high polymer new materials, and active pharmaceutical ingredients sectors, emphasizing innovation-driven growth and product matrix enhancement to increase revenue scale [2] Group 1 - The company is committed to the nutrition products sector [2] - The company is involved in the flavor and fragrance business [2] - The company is developing high polymer new materials [2] Group 2 - The company is engaged in the active pharmaceutical ingredients sector [2] - The company plans to continue deepening its product matrix construction [2] - The company will have new product plans across all segments to enhance revenue [2]
新和成:公司与中石化合资设立宁波镇海炼化新和成生物科技有限公司
Zheng Quan Ri Bao· 2025-09-05 08:41
(文章来源:证券日报) 证券日报网讯新和成9月5日发布公告,在公司回答调研者提问时表示,公司与中石化合资设立宁波镇海 炼化新和成生物科技有限公司,合作投建18万吨/年液体蛋氨酸(折纯)项目,目前已成功产出合格产 品。液体蛋氨酸项目结合前期试产情况定于9月初停产检修,检修时间预计3-4周,后续具体进度将结合 市场需求、试产情况等实际情况推进。 ...
新和成:2025年上半年,公司积极应对复杂多变的国内外环境
Zheng Quan Ri Bao· 2025-09-05 08:41
Core Viewpoint - The company reported a robust growth in key operating metrics for the first half of 2025, driven by effective market expansion and cost management strategies [2] Financial Performance - The company achieved a revenue of 11.1 billion yuan, representing a year-on-year increase of 12.76% [2] - The net profit attributable to shareholders reached 3.603 billion yuan, marking a significant year-on-year growth of 63.46% [2] - The net profit excluding non-recurring items was 3.679 billion yuan, reflecting a year-on-year increase of 70.50% [2] Segment Performance - Revenue from the nutrition products segment grew by 7.78% year-on-year [2] - Revenue from the flavor and fragrance segment increased by 9.35% year-on-year [2] - Revenue from the new materials segment saw a substantial growth of 43.75% year-on-year [2] Strategic Initiatives - The company emphasized its proactive approach to navigating complex domestic and international environments [2] - Efforts to enhance production and sales coordination contributed to improved sales volumes across major products [2] - The company implemented multiple measures to strengthen cost and expense control, leading to growth across all segments [2]
新和成:天津尼龙新材料项目目前尚在项目报批中
Zheng Quan Ri Bao· 2025-09-05 08:40
(文章来源:证券日报) 证券日报网讯新和成9月5日发布公告,在公司回答调研者提问时表示,天津尼龙新材料项目目前尚在项 目报批中,已取得海域权证、能评、主装置环评批复,待合法性报批手续完成后开工建设,计划2027年 建成。 ...
新和成:公司坚持“化工+”“生物+”战略主航道
Zheng Quan Ri Bao Zhi Sheng· 2025-09-05 08:40
Core Viewpoint - The company, Xinhecheng, emphasizes its "Chemicals+" and "Biotechnology+" strategy to seize opportunities in the nutrition, health, new materials, flavoring agents, and active pharmaceutical ingredients sectors [1] Group 1: Strategic Focus - The company is focusing on the development of new products such as serine, tryptophan, and cysteine [1] - The Tianjin nylon new materials project is currently in progress [1] - The company has reserved a thousand acres of land for the planned flavoring project [1] Group 2: Future Plans - Future projects will be advanced based on market conditions, including HA projects and PPS expansion construction [1] - The company has a rich pipeline of reserved projects [1]
新和成涨2.04%,成交额2.34亿元,主力资金净流入2490.86万元
Xin Lang Cai Jing· 2025-09-05 03:14
Core Viewpoint - New Harmony's stock has shown a mixed performance recently, with a year-to-date increase of 12.98% but a decline of 3.49% over the last five trading days, indicating potential volatility in the market [1][2]. Financial Performance - For the first half of 2025, New Harmony achieved a revenue of 11.101 billion yuan, representing a year-on-year growth of 12.76%. The net profit attributable to shareholders was 3.603 billion yuan, marking a significant increase of 63.46% compared to the previous period [2]. - Cumulatively, since its A-share listing, New Harmony has distributed a total of 15.502 billion yuan in dividends, with 5.071 billion yuan distributed over the last three years [3]. Shareholder and Market Activity - As of June 30, 2025, the number of shareholders for New Harmony increased to 80,700, up by 3.59% from the previous period. The average number of circulating shares per shareholder decreased by 3.47% to 37,616 shares [2]. - The stock's trading activity on September 5 showed a net inflow of 24.908 million yuan from main funds, with significant buying from large orders [1]. Company Overview - New Harmony, established on April 5, 1999, and listed on June 25, 2004, is located in Zhejiang Province and specializes in the production and sales of nutritional products, flavoring agents, high polymer new materials, and raw pharmaceuticals [1]. - The company is classified under the basic chemical industry, specifically in chemical products related to food and feed additives [1].
新和成:储备千亩土地规划建设香料项目
Zheng Quan Shi Bao Wang· 2025-09-05 01:15
Core Viewpoint - The company, Xinhecheng, emphasizes its strategic focus on "Chemicals+" and "Biology+" to seize opportunities in the nutrition, health, new materials, flavoring agents, and raw pharmaceutical industries [1] Group 1: Strategic Initiatives - The company has introduced new products such as serine, tryptophan, and cysteine in recent years [1] - The Tianjin nylon new materials project is currently under development [1] - The company has reserved a thousand acres of land for the planning and construction of a flavoring project [1] Group 2: Future Plans - Future projects will be advanced based on market conditions, including the HA project and the expansion of the PPS project [1] - The company has a rich reserve of projects to support its strategic initiatives [1]
新 和 成(002001) - 2025年9月4日投资者关系活动记录表
2025-09-05 00:54
Group 1: Financial Performance - In the first half of 2025, the company achieved a revenue of 11.1 billion yuan, representing a year-on-year growth of 12.76% [3] - The net profit attributable to shareholders reached 3.603 billion yuan, with a year-on-year increase of 63.46% [3] - The non-recurring net profit grew by 70.50% year-on-year [3] - Revenue from the nutrition products, flavor and fragrance, and new materials segments increased by 7.78%, 9.35%, and 43.75% respectively [3] Group 2: Project Developments - The company has established a joint venture with Sinopec to build an 18,000-ton/year liquid methionine project, which has successfully produced qualified products [3] - The Tianjin nylon new materials project is currently in the approval stage, with plans to commence construction in 2027 [3] - The black soil base is focusing on bioproducts, including vitamin C, coenzyme Q10, and various amino acids [4] Group 3: Strategic Focus and Future Plans - The company aims to enhance its product matrix in nutrition, flavor and fragrance, high polymer new materials, and active pharmaceutical ingredients [4] - Future capital expenditure plans include expanding the PPS project and developing a fragrance project on newly acquired land [4] - The company plans to distribute a cash dividend of 6.12 billion yuan for the first half of 2025, subject to shareholder approval [4] Group 4: Market Position and Competitive Strategy - The company focuses on fine chemicals and innovation-driven development, leveraging its chemical and biological platforms [5] - It has achieved domestic production of key products such as vitamin E, vitamin A, PPS, and methionine, contributing to industry transformation [5] - The company emphasizes technological innovation, global layout, and digitalization to enhance its competitive edge [5]